India’s single-specialty healthcare chains are set to triple by 2030

India’s healthcare industry is entering a new phase of consolidation, this time around focused, single-specialty providers rather than sprawling hospital chains.

Organised single-specialty healthcare platforms, from dialysis and fertility clinics to oncology, dental and eyecare networks, are on track to nearly triple in size to more than $12 billion by 2030, according to a new roadmap report by Bessemer Venture Partners. The segment, currently valued at about $4.4 billion, is expected to grow at a 22% compound annual rate, more than twice the pace of the broader healthcare provider market.

The forecast shows a structural shift underway in India’s $54-billion healthcare services market, where capital is increasingly flowing toward narrowly focused care models built for scale, efficiency and repeatable outcomes, rather than capital-heavy, multi-specialty hospitals.

A parallel system takes shape

Multi-specialty hospitals remain indispensable for complex, multidisciplinary treatments. But alongside them, a parallel ecosystem of specialised care providers has been quietly expanding, catering to high-volume procedures that follow standardised clinical pathways.

These businesses are designed around narrow therapeutic areas, dialysis, fertility, cancer care, dental and chronic disease management, allowing them to standardise protocols, train staff efficiently and replicate clinics across cities with far less capital than traditional hospitals.

Bessemer describes these as “specialty-native” platforms: purpose-built networks that prioritise depth of expertise over breadth of services, and scale through hub-and-spoke or clinic-led models rather than large inpatient infrastructure.

The venture firm has already backed several companies aligned with this thesis, including NephroPlus, which operates dialysis centres across India and overseas; fertility platform Pluro; and Sukino, which focuses on continuum and post-acute care.

According to the report, these focused providers are gaining traction for three reasons.

First, patient experience and outcomes tend to improve in repeatable care segments where clinicians perform the same procedures at high volumes. Second, scalability is materially easier: standardised protocols allow networks to expand rapidly into Tier-II cities without reinventing operations each time. Third, the economics are attractive. Many specialty platforms achieve payback periods of 12 to 18 months per centre and sustain EBITDA margins north of 20%, levels that are difficult for full-service hospitals to consistently mat

These advantages are particularly pronounced in segments where demand is rising sharply due to demographic shifts and disease patterns, including chronic kidney disease, infertility, oncology and age-related eye disorders.

A branding vacuum, and an IPO pipeline

Despite their growth, most specialty segments remain fragmented, dominated by local or regional clinics with limited brand recognition. That fragmentation, Bessemer argues, creates an opening for founders to build national champions through a familiar playbook: operational discipline, superior outcomes and consolidation of smaller players through roll-up acquisitions.

If executed well, these platforms could emerge as category leaders with the scale and governance required to tap public markets, or become acquisition targets for established hospital chains seeking to expand into specialised verticals.

“As this market races toward $12 billion, we expect the next generation of iconic Indian healthcare companies will be built one specialty at a time,” said Nithin Kaimal, partner at Bessemer Venture Partners India, adding that winning platforms will need to balance clinical depth with the discipline required to scale sustainably.

For investors, the shift reflects a recalibration of risk and return in Indian healthcare. After years of backing asset-heavy hospital chains with long gestation periods, venture and growth funds are increasingly favouring models that can expand faster, deploy capital more efficiently and demonstrate clearer paths to profitability.

Whether single-specialty providers can maintain clinical quality while scaling aggressively remains a key test. But as India’s healthcare demand grows more specialised—and more price-sensitive—the sector’s centre of gravity appears to be moving away from the mega-hospital and toward focused care, one specialty at a time.